Inhalation Compositions Carrier Particle Optimization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical powder compositions for inhaler devices face challenges in achieving content uniformity, stability, and dosage accuracy due to variations in particle sizes and interactions between active ingredients and carriers, leading to issues with fluidity and agglomeration, which affect the effectiveness and shelf-life of treatments for chronic obstructive pulmonary disease and asthma.
Innovation Solution
The development of dry powder inhalation compositions using specific ratios and particle sizes of fine and coarse lactose and mannitol as carriers, combined with corticosteroids and β2-adrenergic agonists or muscarinic receptor antagonists, to ensure content uniformity, stability, and accurate dosing, while preventing agglomeration and enhancing fluidity for effective pulmonary delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If particle size of active ingredient is reduced to enhance inhalability and lung delivery, then pulmonary delivery efficiency is improved, but content uniformity and dosage accuracy deteriorate due to agglomeration
Solution Approach 1:
The patent introduces carrier particles (such as lactose, mannitol, or sorbitol) as intermediary substances that physically separate and prevent agglomeration of fine active ingredient particles. These carriers act as spacers that maintain uniform distribution while allowing fine particles to be delivered to the lungs, thus resolving the contradiction between particle size reduction and content uniformity.
Solution Approach 2:
The patent creates composite particle systems combining active ingredient particles with carrier particles in specific ratios (e.g., 1:4 to 1:20). This composite approach allows the fine active ingredients to be carried on or mixed with larger carrier particles, maintaining both pulmonary delivery efficiency and content uniformity through the synergistic interaction of different particle sizes and materials.
2Productivity
If carrier particle size is optimized to improve fluidity and filling rate, then manufacturing efficiency is improved, but content uniformity and dosage accuracy deteriorate
Solution Approach 1:
The patent applies different particle size characteristics to different components within the formulation. Carrier particles are selected with specific size ranges (e.g., 10-50 μm for mannitol, 5-20 μm for lactose) that optimize fluidity and filling, while active ingredient particles are kept finer (e.g., <10 μm). This local differentiation of particle qualities allows each component to fulfill its specific function without compromising overall dosage accuracy.
Solution Approach 2:
The patent systematically varies particle size parameters, carrier to active ingredient ratios, and material properties to achieve optimal performance. By adjusting these parameters within specific ranges (e.g., carrier particle size 10-50 μm, active ingredient particle size <10 μm, carrier:active ingredient ratio 1:4 to 1:20), the formulation achieves both improved filling rate and maintained dosage accuracy through quantitative control of physical characteristics.
3Ease of operation
If formulation is designed to prevent agglomeration and improve fluidity, then filling process is improved, but content uniformity and dosage accuracy deteriorate
Solution Approach 1:
Carrier particles serve as intermediary agents that prevent agglomeration of fine active ingredient particles while maintaining uniform distribution. The carriers provide a framework that keeps particles separated during storage and handling, improving fluidity and ease of filling without compromising content uniformity or dosage accuracy when properly formulated.
Solution Approach 2:
The patent develops composite formulations where carrier particles and active ingredient particles are combined in specific ratios and particle size distributions. This composite structure provides both fluidity for easy filling and content uniformity for accurate dosing, as the different particle sizes and materials work together synergistically to achieve multiple objectives simultaneously.
Data Source
AI summary
The invention relates to pharmaceutical powder compositions administered by means of inhalers. More particularly, it relates to pharmaceutical powder compositions having the content uniformity and the desired stability used in inhaler devices.